To discuss how the Biohealth Capital Region would fare out in a potential recession, and whether it can actually avoid one, the I-270 Innovation Labs brought together an outstanding group of regional experts from across key sectors connected to both industries.
For many life sciences companies, access to capital can be difficult at times. However, where there may be obstacles, opportunities can be found. That’s the philosophy of BroadOak Capital Partners’ Bill Snider, who leads the Bethesda, Maryland-based firm’s growth capital investing activities. One of the founders of BroadOak, Snider said the firm’s vision has been to be something of a merchant bank, providing financial support and advice for the tools and diagnostics products companies operating in the life sciences. As a modern-day merchant bank, Snider said the firm wanted to be flexible in order to provide the best advice for their clients. Clients include those companies that focus on research tools and consumables, diagnostics, biopharma services, and adjacent markets.
PhenoVista Biosciences announced today that it has secured funding from BroadOak Capital Partners, a life science-focused investor. Since its founding in 2014, PhenoVista has democratized access to high-content analysis of physiologically relevant cell models. The investment will be used to develop new complex products, such as models of the blood-brain barrier and platforms for better understanding neurodegenerative diseases.
SAN JOSE, Calif. & BETHESDA, Md.–(BUSINESS WIRE)–Accellix Inc., which provides quick and accurate flow cytometry results in a compact and easy-to-use platform designed for use by cell therapy companies on the manufacturing floor and at the point-of-need, today announced that it has raised $10 million from BroadOak Capital Partners.
Bill Snider is a Partner at BroadOak and leads the firm’s growth capital investing activities. Mr. Snider has more than 25 years of institutional investment experience.
Bryan Poltilove is a Managing Director focused on guiding BroadOak’s growth capital investing strategy and advising portfolio companies in the life sciences and cell and gene therapy sectors.
